

Luminex[®] 100[™] and Luminex[®] 200[™] Systems



| xTAG [®] Cystic Fibrosis (CFTR) |
|--|
| 39 kit v2 and 60 kit v2 |

Your Choice for Cystic Fibrosis Testing

The benefits of xTAG[®] Cystic Fibrosis Kits include:

- Comprehensive Mutation coverage, including ACMG/ACOG recommended panel. Multiplex genotyping no reflex testing necessary.
- Flexibility Mutation panel selection through the software.
- Confidence Second generation IVD assay with 100% overall accuracy^{*} and >99% precision after allowable re-runs.
- Ease of Use Streamlined protocol with minimal hands-on time.

* Accuracy of 100% for genotyping information used for carrier and newborn screening.

CFTR Mutation Detection—Choose your assay. Choose your coverage.

xTAG[®] Cystic Fibrosis (CFTR) 39 kit v2

xTAG[®] Cystic Fibrosis (CFTR) 60 kit v2

| ACMG Recommended Mutations ¹ | | 16 Most Common Additional Mutations [⊷] | | | Broad Ethnic Coverage | | erage | |
|--|-----------|---|----------|-----------|-----------------------|------------|----------|------------|
| ΔF508 | A455E | R1162X | 1078delT | 1898+5G>T | | CFTRdel2,3 | G330X | L206W |
| ΔΙ507 | 1717-1G>A | 3659delC | 394delTT | 2183AA>G | | E60X | Q890X | 2055del9>A |
| G542X | R560T | 3849+10kbC>T | Y122X | 2307insA | | R75X | K710X | R1158X |
| G85E | R553X | W1282X | R347H | Y1092X | | 2143delT | S1196X | 935delA |
| R117H | G551D | N1303K | V520F | M1101K | + | 406-1G>A | 3199del6 | 3791delC |
| 621+1G>T | 1898+1G>A | 5/7/9T | A559T | S1255X | | Q493X | R1066C | |
| 711+1G>T | 2184delA | F508C | S549N | 3876delA | | 1677delTA | W1089X | |
| R334W | 2789+5G>A | 1507V | S549R | 3905insT | | G178R | D1152H | |
| R347P | 3120+1G>A | 1506V | | | | | | |

¹ Genet Med. 2004 Sep-Oct; 6(5):387-91.

** List of mutations or variants identified in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

CF Mutation Detection Rate (%) [§]

| Ethnic Group | Incidence of CF | Carrier Frequency | ACMG Recommended Mutation Only | xTAG® Cystic Fibrosis (CFTR) 39 kit v2 | xTAG® Cystic Fibrosis (CFTR) 60 kit v2 |
|---------------------|--------------------|----------------------|---|---|---|
| Caucasian | 1 in 3,200 | 1 in 25 | 88.3 | 89.7 | 90.6 |
| Hispanic Americans | 1 in 9,500 | 1 in 46 | 71.7 | 73.4 | 83.7 |
| African Americans | 1 in 15,300 | 1 in 65 | 64.5 | 68.6 | 72.5 |
| Ashkenazi Jewish | 1 in 3,300 | 1 in 25 | 94.0 | 94.0 | 95.9 |
| Asian Americans | 1 in 32,100 | 1 in 90 | 48.9 | 54.5 | 54.5 |

\$ Data collected from the following references: Watson et al. Genet Med 2004;6(5):387-91, Richards et al. Genet Med 2002;4(5):379-391, Bobadilla et al. Human Mutat 2002;19:575-606, Heim et al. Genet Med 2001;3:168-76, Sugarman et al. Genet Med 2004;6:392-99, Organ et al. Genet Testing 2001;5:47-52, Wong et al. Human Mutat 2001;18:296-307, Alder et al. Human Mutat 2004 MIB #752, and Shriver et al. JMD 2005;7:289-99.

Assay Description

The xTAG Cystic Fibrosis kits are used to simultaneously detect and identify a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human blood specimens. The panels include mutations and variants recommended by the American College of Medical Genetics and American College of Obstetricians and Gynecologists (ACMG/ACOG), as well as some of the world's most common and North American-prevalent mutations. The kits are qualitative genotyping tests which provide information intended to be used for carrier testing in adults of reproductive age, as an aid in newborn screening, and in confirmatory diagnostic testing in newborns and children.

The kits are not indicated for use in fetal diagnostic or pre-implantation testing. The kits are also not indicated for stand-alone diagnostic purposes.

Ordering Information

| Product Name | Part Number | | |
|--|-------------|--|--|
| xTAG [®] Cystic Fibrosis (CFTR) 39 kit v2 | I027C0231 | | |
| xTAG® Cystic Fibrosis (CFTR) 60 kit v2 | I024C0181 | | |

Products are FDA Cleared for IVD use.

References:

1. Luminex Corporation | xTAG Cystic Fibrosis (CFTR) 39 kit v2 (US-IVD) Package Insert

2. Luminex Corporation | xTAG Cystic Fibrosis (CFTR) 60 kit v2 (US-IVD) Package Insert



orders@luminexcorp.com or support@luminexcorp.com

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence. For a complete list of warnings and precautions, consult the package insert. The Luminex 100/200 is a class 1(1) laser product. ©2023 Luminex Corporation. *A DiaSorin Company*. All rights reserved. Luminex and xTAG are trademarks of Luminex Corporation, registered in the U.S. and other

©2023 Luminex Corporation. A DiaSorin Company. All rights reserved. Luminex and xTAG are trademarks of Luminex Corporation, registered in the U.S. and other countries. Luminex 100 and Luminex 200 are trademarks Luminex Corporation.

www.luminexcorp.com/cf

HEADQUARTERS UNITED STATES +1 512 219 8020 info@luminexcorp.com

EUROPE +31 73 800 1900 europe@luminexcorp.com

CANADA +1 416 593 4323 info@luminexcorp.com CHINA +86 21 802 31150 infocn@luminexcorp.com JAPAN +81 3 5545 7440 infojp@luminexcorp.com \$\$\$50153.0923